Vulvovaginal Candidiasis - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Vulvovaginal Candidiasis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Vulvovaginal Candidiasis - Pipeline Review, H2 2016', provides an overview of the Vulvovaginal Candidiasis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis
- The report reviews pipeline therapeutics for Vulvovaginal Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Vulvovaginal Candidiasis therapeutics and enlists all their major and minor projects
- The report assesses Vulvovaginal Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Vulvovaginal Candidiasis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding  Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Vulvovaginal Candidiasis Overview 7
Therapeutics Development 8
Pipeline Products for Vulvovaginal Candidiasis - Overview 8
Vulvovaginal Candidiasis - Therapeutics under Development by Companies 9
Vulvovaginal Candidiasis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Vulvovaginal Candidiasis - Products under Development by Companies 13
Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development 14
Cidara Therapeutics, Inc. 14
Grupo Ferrer Internacional, S.A. 15
NovaDigm Therapeutics, Inc. 16
Scynexis, Inc. 17
TGV-Laboratories 18
Viamet Pharmaceuticals, Inc. 19
Vulvovaginal Candidiasis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
(clotrimazole + diclofenac sodium) - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
arasertaconazole - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CD-101 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
MH-010 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Myc-102 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
NDV-3 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
NDV-3A - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
SCY-078 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
TOL-463 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
VT-1161 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Vulvovaginal Candidiasis - Dormant Projects 48
Vulvovaginal Candidiasis - Discontinued Products 49
Vulvovaginal Candidiasis - Product Development Milestones 50
Featured News & Press Releases 50
Aug 15, 2016: NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal Immunotherapy in a Phase 2a Study in Women with Recurrent Vulvovaginal Candidiasis 50
Aug 10, 2016: Positive Interim Clinical Results for VT-1161 to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting 51
Aug 09, 2016: Cidara Therapeutics Announced Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting 51
Aug 08, 2016: SCYNEXIS Reports Second Quarter 2016 Financial Results and Provides Company Update 52
Jun 09, 2016: Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis 53
Jun 08, 2016: Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016 54
Jun 08, 2016: SCYNEXIS Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors 55
May 31, 2016: FDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics Novel Antifungal Product Candidate 56
Mar 09, 2016: Viamet Reports Positive Results from Interim Analysis of REVIVE Phase 2b Trial of VT-1161 in Recurrent Vulvovaginal Candidiasis 57
Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections 58
Jan 11, 2016: Cidara Therapeutics Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CD101 IV 59
Dec 01, 2015: SCYNEXIS Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis 59
Jul 29, 2015: Viamet to Present at Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting 60
Apr 24, 2015: Viamet to Provide Update on VT-1161, Novel Antifungal Program at ECCMID 2015 60
Feb 12, 2015: Viamet Announces Initiation of REVIVE Phase 2b Study of VT-1161 in Recurrent Vulvovaginal Candidiasis 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Number of Products under Development for Vulvovaginal Candidiasis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Comparative Analysis by Unknown Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Vulvovaginal Candidiasis - Pipeline by Cidara Therapeutics, Inc., H2 2016 14
Vulvovaginal Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016 15
Vulvovaginal Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2016 16
Vulvovaginal Candidiasis - Pipeline by Scynexis, Inc., H2 2016 17
Vulvovaginal Candidiasis - Pipeline by TGV-Laboratories, H2 2016 18
Vulvovaginal Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Assessment by Combination Products, H2 2016 21
Number of Products by Stage and Target, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Vulvovaginal Candidiasis - Dormant Projects, H2 2016 48
Vulvovaginal Candidiasis - Discontinued Products, H2 2016 49